Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( TWINKLE )
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.70135 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Tetsuya Babazono und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Hypoglycemic Agents, Biomarkers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sumitomo Pharma Co., Ltd., Dainippon Sumitomo Pharma.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim To evaluate the long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD). Materials and Methods This open‐label, single‐arm, multicenter, phase 4 study (TWINKLE) enrolled individuals with T2D and estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m 2 , treated with ≤1 oral hypoglycemic agent. Participants received 500 mg of imeglimin twice daily if eGFR was 15 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Department of Internal Medicine, Naka Kinen Clinic, Naka, Ibaraki, Japan.
- Department of Endocrinology and Diabetes, Meitetsu Hospital, Nagoya, Japan.
- Division of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Tokyo, Japan.
- Department of Internal Medicine, Nakamoto Naika Clinic, Mito, Ibaraki, Japan.
- Department of General Internal Medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto, Japan.
ORCID-Profile: Katsuhiko Hagi
Förderung
- Sumitomo Pharma Co., Ltd.
- Dainippon Sumitomo Pharma
Zitieren
APA
Babazono, T., Osonoi, T., Okamoto, H., Onishi, Y., Nakamoto, S., Kashima, M., Kawanami, D., Nakashima, E., Watabe, K., Nunami, N., & Hagi, K. (2025). Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( TWINKLE ). Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70135
Vancouver
Babazono T, Osonoi T, Okamoto H, Onishi Y, Nakamoto S, Kashima M, et al. Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( TWINKLE ). Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.70135
BibTeX
@article{Babazono2025,
author = {Babazono, Tetsuya and Osonoi, Takeshi and Okamoto, Hideki and Onishi, Yukiko and Nakamoto, Shinya and Kashima, Masayuki and Kawanami, Daiji and Nakashima, Eitaro and Watabe, Kei and Nunami, Noriko and Hagi, Katsuhiko},
title = {Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( TWINKLE )},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.70135}
}
EUVIMED